By Ryan Davis ( August 5, 2014, 5:37 PM EDT) -- A California federal judge has tossed Takeda Pharmaceutical Co. Ltd.'s claim seeking declaratory judgment that Mylan Inc.'s planned generic version of the acid reflux drug Dexilant will infringe its patents, saying it "serves no purpose" since Takeda also alleges infringement under the Hatch-Waxman Act....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.